Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
Avalyn Pharma
Apr 30, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
Parexel has acquired Vitrana, a healthcare IT business in North Carolina. Vitrana provides an AI-enabled, end-to-end pharmacovigilance technology platform that supports patient safety workflows, including intelligent automation for PV case processing and compliance. Parexel acquisitions in healthcare IT aim to integrate system-agnostic safety technology with existing safety databases to improve accuracy and cycle times for regulatory and post-approval safety operations. The Vitrana acquisition is an add-on acquisition by strategic buyer Parexel, with financial terms undisclosed and announced status, expanding Parexel’s patient safety services with technology-enabled PV services and streamlined SAE reconciliation.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Avalyn Pharma
Apr 30, 2026
Avalyn Pharma
Apr 30, 2026
Chiesi Group→KalVista Pharmaceuticals
Apr 29, 2026
CareDx→Naveris
Apr 29, 2026
Sapho Bio
Apr 29, 2026